NCT03311334: A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

NCT03311334
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H, MMR, HLA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have tumors that express HLA-A*02:01, HLA-A*02:06, or HLA-A*24:02; Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase)
Exclusions: Patients with known untreated symptomatic brain metastases that require treatment – see trial for details; Patients who have received prior treatment with any other anti-PD-1/L1/L2 agent or drugs targeting other immuno-regulatory receptors or mechanisms (e.g. antibodies against CTLA-4, LAG-3, IDO, PD-L1, IL-2R, GITR); Patients who have received prior treatment with any other Wilms Tumor 1 (WT1)-related agents including peptide vaccine, dendric cell vaccine, and gene therapy
https://ClinicalTrials.gov/show/NCT03311334

Comments are closed.

Up ↑